Clinical Trials
21 trialsNCT00102648 2024-10-17
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00020774 2020-07-31
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00102635 2018-11-15
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00005030 2018-11-14
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00047502 2018-11-07
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00038584 2018-10-30
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00038597 2018-10-30
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00038493 2018-10-29
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00773474 2016-02-18
Lonafarnib in Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00050336 2015-08-27
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT00109538 2015-05-01
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT00081510 2015-04-15
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00083096 2015-02-10
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Unknown
NCT00539968 2015-02-05
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00003956 2013-04-04
Combination Chemotherapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00612651 2013-02-20
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Duke University
Phase 1 Completed
NCT00288444 2012-12-18
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Emory University
Phase 1 Terminated
NCT00006351 2012-09-24
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00068757 2012-09-12
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT00281515 2012-06-29
Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer
AGO Study Group
Phase 2 Completed
NCT00015899 2009-10-14
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Pediatric Brain Tumor Consortium
Phase 1 Completed